Cargando…
Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study
BACKGROUND: Besides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627016/ https://www.ncbi.nlm.nih.gov/pubmed/34869959 http://dx.doi.org/10.1016/j.idm.2021.11.002 |
_version_ | 1784606772091158528 |
---|---|
author | Mahmud, Md Shahriar Kamrujjaman, Md Adan, Md Mashih Ibn Yasin Hossain, Md Alamgir Rahman, Md Mizanur Islam, Md Shahidul Mohebujjaman, Muhammad Molla, Md Mamun |
author_facet | Mahmud, Md Shahriar Kamrujjaman, Md Adan, Md Mashih Ibn Yasin Hossain, Md Alamgir Rahman, Md Mizanur Islam, Md Shahidul Mohebujjaman, Muhammad Molla, Md Mamun |
author_sort | Mahmud, Md Shahriar |
collection | PubMed |
description | BACKGROUND: Besides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates, the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates. In this article, a mathematical model study has been done on the importance of vaccination and vaccine efficiency rate during an ongoing pandemic. METHODS: We simulated a five compartment mathematical model to analyze the pandemic scenario in both California, and whole U.S. We considered four vaccines, Pfizer (95%), Moderna (94%), AstraZeneca (79%), and Johnson & Johnson (72%), which are being used rigorously to control the SARS-CoV-2 pandemic, in addition with two special cases: a vaccine with 100% efficacy rate and no vaccine under use. SARS-CoV-2 related data of California, and U.S. were used in this study. FINDINGS: Both the infection and death rates are very high in California. Our model suggests that the pandemic situation in California will be under control in the last quartile of the year 2023 if vaccination program is continued with the Pfizer vaccine. During this time, six waves may happen from the beginning of the immunization where the case fatality and recovery rates will be 1.697% and 98.30%, respectively. However, according to the considered model, this period might be extended to the mid of 2024 when vaccines with lower efficacy rates are used. On the other hand, the daily cases and deaths in the U.S. will be under control at the end of 2026 with multiple waves. Although the number of susceptible people will fall down to none in the beginning of 2027, there is less chance to stop the vaccination program if vaccinated with a vaccine other than a 100% effective vaccine or Pfizer, and at that case vaccination program must run till the mid of 2028. According to this study, the unconfirmed-infectious and infected cases will be under control at the end of 2027 and at the mid of 2028, respectively. INTERPRETATION: The more effective a vaccine is, the less people suffer from this malign infection. Vaccines which are less than 90% effective do not have notable contribution to control the pandemic besides hard immunity. Furthermore, specific groups of people are getting prioritized initially, mass vaccination and quick responses are required to control the spread of this disease. |
format | Online Article Text |
id | pubmed-8627016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-86270162021-11-29 Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study Mahmud, Md Shahriar Kamrujjaman, Md Adan, Md Mashih Ibn Yasin Hossain, Md Alamgir Rahman, Md Mizanur Islam, Md Shahidul Mohebujjaman, Muhammad Molla, Md Mamun Infect Dis Model Vaccination and Mutation BACKGROUND: Besides maintaining health precautions, vaccination has been the only prevention from SARS-CoV-2, though no clinically proved 100% effective vaccine has been developed till date. At this stage, to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates, the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates. In this article, a mathematical model study has been done on the importance of vaccination and vaccine efficiency rate during an ongoing pandemic. METHODS: We simulated a five compartment mathematical model to analyze the pandemic scenario in both California, and whole U.S. We considered four vaccines, Pfizer (95%), Moderna (94%), AstraZeneca (79%), and Johnson & Johnson (72%), which are being used rigorously to control the SARS-CoV-2 pandemic, in addition with two special cases: a vaccine with 100% efficacy rate and no vaccine under use. SARS-CoV-2 related data of California, and U.S. were used in this study. FINDINGS: Both the infection and death rates are very high in California. Our model suggests that the pandemic situation in California will be under control in the last quartile of the year 2023 if vaccination program is continued with the Pfizer vaccine. During this time, six waves may happen from the beginning of the immunization where the case fatality and recovery rates will be 1.697% and 98.30%, respectively. However, according to the considered model, this period might be extended to the mid of 2024 when vaccines with lower efficacy rates are used. On the other hand, the daily cases and deaths in the U.S. will be under control at the end of 2026 with multiple waves. Although the number of susceptible people will fall down to none in the beginning of 2027, there is less chance to stop the vaccination program if vaccinated with a vaccine other than a 100% effective vaccine or Pfizer, and at that case vaccination program must run till the mid of 2028. According to this study, the unconfirmed-infectious and infected cases will be under control at the end of 2027 and at the mid of 2028, respectively. INTERPRETATION: The more effective a vaccine is, the less people suffer from this malign infection. Vaccines which are less than 90% effective do not have notable contribution to control the pandemic besides hard immunity. Furthermore, specific groups of people are getting prioritized initially, mass vaccination and quick responses are required to control the spread of this disease. KeAi Publishing 2021-11-27 /pmc/articles/PMC8627016/ /pubmed/34869959 http://dx.doi.org/10.1016/j.idm.2021.11.002 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Vaccination and Mutation Mahmud, Md Shahriar Kamrujjaman, Md Adan, Md Mashih Ibn Yasin Hossain, Md Alamgir Rahman, Md Mizanur Islam, Md Shahidul Mohebujjaman, Muhammad Molla, Md Mamun Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title | Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title_full | Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title_fullStr | Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title_full_unstemmed | Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title_short | Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020–2026: A modeling study |
title_sort | vaccine efficacy and sars-cov-2 control in california and u.s. during the session 2020–2026: a modeling study |
topic | Vaccination and Mutation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627016/ https://www.ncbi.nlm.nih.gov/pubmed/34869959 http://dx.doi.org/10.1016/j.idm.2021.11.002 |
work_keys_str_mv | AT mahmudmdshahriar vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT kamrujjamanmd vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT adanmdmashihibnyasin vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT hossainmdalamgir vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT rahmanmdmizanur vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT islammdshahidul vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT mohebujjamanmuhammad vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy AT mollamdmamun vaccineefficacyandsarscov2controlincaliforniaandusduringthesession20202026amodelingstudy |